Wockhardt eyes USD 7 billion market opportunity for antibiotic Zaynich in US, Europe

Wockhardt's new antibiotic, Zaynich, targeting gram-negative infections, anticipates a significant USD 7 billion market in the US and Europe. Following a successful pre-NDA meeting with the USFDA, the company plans to file for approval this quarter, aiming for a launch in FY27.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SqXFZtA
via IFTTT